Transamin's benefit in decreasing blood loss in knee prosthesis patients

Not Applicable

• Conditions: G09.188.130; Tranexamic acid; hemorrhage; blood transfusion; blood volume; D02.241.223.268.860; C23.550.414; E02.095.135

• Registration Number: RBR-4dvhts
• Lead Sponsor: Fundacao Hospital Adriano Jorge

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2019-10-16
• Last Update Posted: 29 May 2023

Recruitment & Eligibility

• Status: Recruitment completed
• Sex: Not specified
• Target Recruitment: Not specified

Inclusion Criteria

Patients were regularly enrolled in the institution where the study was performed with a classic indication of TKA, recommended by Camanho: medial or lateral clamping with obliteration of the joint space, deviations in femoro-tibial varus greater than 15º; deviations in femoro-tibial valgus greater than 10º; femorotibial subluxation in the frontal plane greater than 10 mm; anteriorization of the tibia in relation to the femur in the profile radiography; severe involvement of two of the three knee joint compartments (femorotibial medial, femorotibial lateral or femoropatellar), and failure of conservative treatment for at least three months, when these criteria were not fulfilled. Patients with primary degenerative knee OA; for this evaluation, the patients with stage of knee arthrosis III were considered, according to Ählback, modified by Keys

Exclusion Criteria

Patients who underwent knee prosthesis revision surgery, who did not use medial articular access, patients not operated by the senior surgeon, patients with rheumatoid arthritis, multiple scars, and those who refused to sign or did not understand were excluded from the study. TCLE. Any patient with decompensated diabetes mellitus (fasting glycemia> 140 mg / dL), uncontrolled systemic hypertension (SBP > 200 mmHg), peripheral vascular disease, previous thromboembolic events, acute myocardial infarction, neoplasia, active infection, rheumatoid arthritis, obese with (American Society of Anesthesiologists - ASA score> III) and use of anticoagulants had their clinical condition reassessed and surgical procedure postponed. Patients who declared themselves indigenous

Study & Design

• Study Type: Intervention
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The use of tranexamic acid is expected to reduce postoperative bleeding after total knee arthroplasty. When blood loss was compared with the groups treated with and without tranexamic acid that underwent total knee arthroplasty (Blood volume in the suction drain was measured serially at three, six, 12, and 14 hours after surgery). ). In all periods measured after surgery, there was a greater bleeding in Group II patients, but with statistically significant difference at three, six and 12 hours (p <0.05)